Save information for later
Sign Up

Learn About Nonalcoholic Steatohepatitis (NASH)

View Main Condition: Non-Alcoholic Fatty Liver Disease

What is the definition of Nonalcoholic Steatohepatitis (NASH)?
Nonalcoholic steatohepatitis is an advanced stage of nonalcoholic fatty liver disease that occurs in individuals who do not abuse alcohol. In nonalcoholic steatohepatitis, a buildup of fat in the liver causes it to become inflamed and damaged.
What are the symptoms of Nonalcoholic Steatohepatitis (NASH)?
Early nonalcoholic steatohepatitis may not have any symptoms. Symptoms of nonalcoholic steatohepatitis that has progressed include weakness, fatigue, unexplained weight loss, and pain the upper right abdomen. Symptoms of severe nonalcoholic steatohepatitis may include symptoms of cirrhosis (scarring of the liver), such as constant itchiness, behavior changes, confusion, drowsiness, slurred speech, yellowing of the skin and whites of eyes, spider veins, easy bruising, bleeding, fluid in the abdomen, swelling of the legs and feet, an enlarged liver and/or spleen, enlarged esophageal veins, portal hypertension, and liver failure.
Not sure about your diagnosis?
Check Your Symptoms
What are the current treatments for Nonalcoholic Steatohepatitis (NASH)?
There is currently no cure for nonalcoholic steatohepatitis. Treatment for nonalcoholic steatohepatitis is focused on managing associated conditions that contribute to or worsen the disease, such as high cholesterol levels, diabetes, drinking alcohol, and obesity. Treatment for nonalcoholic steatohepatitis includes lowering cholesterol levels, losing weight, eating a healthy diet, controlling diabetes, stopping alcohol use, drinking coffee daily, and regular exercise.
Who are the top Nonalcoholic Steatohepatitis (NASH) Local Doctors?
Hepatology
Hepatology

Mgmc LLC

621 Ridgely Ave, Suite 201, 
Annapolis, MD 
 1.8 mi
Offers Telehealth

Arul Thomas is a Hepatologist in Annapolis, Maryland. Dr. Thomas has been practicing medicine for over 17 years and is rated as an Advanced provider by MediFind in the treatment of Nonalcoholic Steatohepatitis (NASH). His top areas of expertise are Hepatitis, Hepatitis C, Cirrhosis, Endoscopy, and Liver Transplant.

Gastroenterology
Gastroenterology

Chesapeake Digestive Associates, PC

621 Ridgely Ave, Suite 201, 
Annapolis, MD 
 1.8 mi

Barry Cukor is a Gastroenterologist in Annapolis, Maryland. Dr. Cukor and is rated as an Experienced provider by MediFind in the treatment of Nonalcoholic Steatohepatitis (NASH). His top areas of expertise are Gastroesophageal Reflux Disease (GERD), Gas Bloat Syndrome, Trichohepatoenteric Syndrome, Gastrectomy, and Endoscopy.

 
 
 
 
Learn about our expert tiers
Learn More
Gastroenterology
Gastroenterology

Chesapeake Digestive Associates, PC

621 Ridgely Ave, Suite 201, 
Annapolis, MD 
 1.8 mi

Charles King is a Gastroenterologist in Annapolis, Maryland. Dr. King and is rated as an Experienced provider by MediFind in the treatment of Nonalcoholic Steatohepatitis (NASH). His top areas of expertise are Angiodysplasia of the Colon, Esophagitis, Gastroesophageal Reflux Disease (GERD), Colonoscopy, and Endoscopy.

What are the latest Nonalcoholic Steatohepatitis (NASH) Clinical Trials?
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Efruxifermin in Subjects With Non-Cirrhotic Nonalcoholic Steatohepatitis (NASH)/Metabolic Dysfunction-Associated Steatohepatitis (MASH) and Fibrosis

Summary: This is a multi-center evaluation of efruxifermin (EFX) in a randomized, double-blind, placebo-controlled study in subjects with non-cirrhotic NASH/MASH and fibrosis stage 2 or 3 (F2 or F3). The study will enroll subjects in two cohorts for a total samples size of 1650 subjects.

Match to trials
Find the right clinical trials for you in under a minute
Get started
Non-alcoholic Steatohepatitis Registry Platform Study

Summary: This is a multi-center, prospective, observational registry platform study aimed at describing the clinical characteristics and diagnosis and treatment patterns of Chinese patients with nonalcoholic steatohepatitis (NASH) with fibrosis.